Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab with radiotherapy vs radiotherapy alone in primary squamous cell carcinoma of the head and neck
2007-002097-61Phase 3Completed
- Sponsor
- Danish Head and Neck Cancer Group
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zalutumumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Danish Head and Neck Cancer Group. Primary endpoint: Loco-regional control at 5 years after radiotherapy. Started Jun 2007; status: completed.
02
Drugs
zalutumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-002097-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002097-61.